Pharmacoeconomic issues in the treatment of depression.

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The goal of pharmacoeconomics is to define the cost and value of different treatment strategies. The cost-effectiveness analysis, one model used in the study of pharmacoeconomics, considers not only the cost of the drug itself, but also the labor costs associated with physician and pharmacy visits, and expenses for laboratory testing. Drugs that require more intensive medical surveillance, either for dose adjustments or overall management of treatment-related side effects, can escalate costs. In the case of antidepressant drugs, various cost-effectiveness analyses have shown that the total cost of disease management is similar for generic tricyclics and the more expensive selective serotonin reuptake inhibitors. This outcome is due to the higher labor costs associated with tricyclics that offset their acquisition cost advantage. The application of cost-effectiveness studies in formulary decision-making and clinical practice guidelines, will maximize the use of health care resources.

Original languageEnglish
JournalFormulary (Cleveland, Ohio)
Volume30 Suppl 1
StatePublished - 1 Sep 1995

Fingerprint

Pharmaceutical Economics
Costs and Cost Analysis
Cost-Benefit Analysis
Drug Costs
Therapeutics
Formularies
Cost of Illness
Health Resources
Serotonin Uptake Inhibitors
Disease Management
Practice Guidelines
Antidepressive Agents
Delivery of Health Care
Physicians
Pharmaceutical Preparations

Cite this

@article{16f10d022f7c4b7fa112e1335711c17b,
title = "Pharmacoeconomic issues in the treatment of depression.",
abstract = "The goal of pharmacoeconomics is to define the cost and value of different treatment strategies. The cost-effectiveness analysis, one model used in the study of pharmacoeconomics, considers not only the cost of the drug itself, but also the labor costs associated with physician and pharmacy visits, and expenses for laboratory testing. Drugs that require more intensive medical surveillance, either for dose adjustments or overall management of treatment-related side effects, can escalate costs. In the case of antidepressant drugs, various cost-effectiveness analyses have shown that the total cost of disease management is similar for generic tricyclics and the more expensive selective serotonin reuptake inhibitors. This outcome is due to the higher labor costs associated with tricyclics that offset their acquisition cost advantage. The application of cost-effectiveness studies in formulary decision-making and clinical practice guidelines, will maximize the use of health care resources.",
author = "Cohen, {Lawrence J.}",
year = "1995",
month = "9",
day = "1",
language = "English",
volume = "30 Suppl 1",
journal = "Formulary (Cleveland, Ohio)",
issn = "1082-801X",
publisher = "Advanstar Communications Inc.",

}

Pharmacoeconomic issues in the treatment of depression. / Cohen, Lawrence J.

In: Formulary (Cleveland, Ohio), Vol. 30 Suppl 1, 01.09.1995.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pharmacoeconomic issues in the treatment of depression.

AU - Cohen, Lawrence J.

PY - 1995/9/1

Y1 - 1995/9/1

N2 - The goal of pharmacoeconomics is to define the cost and value of different treatment strategies. The cost-effectiveness analysis, one model used in the study of pharmacoeconomics, considers not only the cost of the drug itself, but also the labor costs associated with physician and pharmacy visits, and expenses for laboratory testing. Drugs that require more intensive medical surveillance, either for dose adjustments or overall management of treatment-related side effects, can escalate costs. In the case of antidepressant drugs, various cost-effectiveness analyses have shown that the total cost of disease management is similar for generic tricyclics and the more expensive selective serotonin reuptake inhibitors. This outcome is due to the higher labor costs associated with tricyclics that offset their acquisition cost advantage. The application of cost-effectiveness studies in formulary decision-making and clinical practice guidelines, will maximize the use of health care resources.

AB - The goal of pharmacoeconomics is to define the cost and value of different treatment strategies. The cost-effectiveness analysis, one model used in the study of pharmacoeconomics, considers not only the cost of the drug itself, but also the labor costs associated with physician and pharmacy visits, and expenses for laboratory testing. Drugs that require more intensive medical surveillance, either for dose adjustments or overall management of treatment-related side effects, can escalate costs. In the case of antidepressant drugs, various cost-effectiveness analyses have shown that the total cost of disease management is similar for generic tricyclics and the more expensive selective serotonin reuptake inhibitors. This outcome is due to the higher labor costs associated with tricyclics that offset their acquisition cost advantage. The application of cost-effectiveness studies in formulary decision-making and clinical practice guidelines, will maximize the use of health care resources.

UR - http://www.scopus.com/inward/record.url?scp=0001932242&partnerID=8YFLogxK

M3 - Article

C2 - 10151739

AN - SCOPUS:0001932242

VL - 30 Suppl 1

JO - Formulary (Cleveland, Ohio)

JF - Formulary (Cleveland, Ohio)

SN - 1082-801X

ER -